As with Moderna, which the panel voted to authorize for booster shots Thursday, the whole process could conclude next week at the earliest.
Another pertinent debate that the FDA panel took on Friday was the potential benefits of mixing and matching vaccines for booster shots.The non-peer reviewed study evaluated all three vaccines -- Pfizer, Moderna and J&J -- and found that no matter the booster, all study participants saw a "substantial" uptick in antibody levels after a booster shot.For now, the process will formally move forward with authorizing additional booster doses of Moderna and Johnson & Johnson shots for those who received the same original vaccine, as was the case with the Pfizer booster authorization.That panel has scheduled a meeting for next Wednesday and Thursday to discuss boosters for Moderna and Johnson & Johnson.